Who We Are
Cognition Therapeutics is focused on developing innovative therapies that improve the lives of individuals with Alzheimer’s disease and other neurocognitive disorders. We deeply thank the patients, families, clinical researchers, hospitals, and clinics that participate in clinical trials that are designed to test our lead drug candidate, CT1812. Every patient who participates allows us to learn more about the safety and effectiveness of this experimental medicine and contributes to the overall understanding of Alzheimer’s disease. This benefits all current and future patients, and both directly and indirectly their families and caregivers.
Who We Serve
Languages Spoken
English
Service Area(s)
Nationwide
Age Requirements
No Age Requirement
Available 24/7
No
Intake Process
Call or email for information.
Self Refer
Yes
Provider Refer
Yes
Intake Contact Telephone
(412) 481-2210
Report Problems
Call the Agency